Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 open-label study of AZD9833 in Japanese women with ER-positive, HER2-negative advanced breast cancer
jRCT2080225373Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Aug 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of camizestrant in breast cancer, sponsored by AstraZeneca. Primary endpoints: Safety and tolerability of AZD9833, Pharmacokinetics of AZD9833 and 1 more. Started Aug 2020; status: completed.
02
Drugs
camizestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on jRCT2080225373.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225373.